Telehealth Ketamine for Anxiety

Anxiety disorders are among the most common mental health conditions, and a significant proportion of patients do not achieve adequate relief with standard treatments—SSRIs, SNRIs, benzodiazepines, or CBT. Ketamine is increasingly used for anxiety, though the evidence base is less developed than for depression. This guide covers what is known, what is not, and how to evaluate telehealth ketamine for anxiety.

The Evidence for Ketamine in Anxiety

What Research Shows

The research on ketamine for anxiety is promising but less robust than for treatment-resistant depression. Key findings include:

• Several open-label studies and small randomized trials have demonstrated rapid anxiolytic (anxiety-reducing) effects from ketamine, often within hours of treatment
• Effects appear similar in mechanism to antidepressant effects—glutamate system modulation, BDNF release, and rapid change in connectivity between fear-processing regions and the prefrontal cortex
• Ketamine's efficacy seems strongest for anxiety disorders with significant comorbid depression (which is the majority of treatment-resistant cases)
• Social anxiety, generalized anxiety disorder (GAD), and treatment-resistant panic disorder have all been studied

Limitations of the Evidence

• Most anxiety trials are small (fewer than 50 patients)
• Few are randomized, double-blind, controlled trials
• The durability of anxiolytic effects is less well-characterized than for depression
• Anxiety conditions are heterogeneous—results for GAD may not apply to social anxiety or OCD

Patients seeking ketamine specifically for anxiety without comorbid depression should discuss with their provider the strength of evidence for their specific anxiety diagnosis. For help evaluating whether telehealth is the right modality, see is telehealth ketamine right for you.

Anxiety Disorders That May Respond

Generalized Anxiety Disorder (GAD)

GAD—characterized by persistent, difficult-to-control worry across multiple domains—has some evidence supporting ketamine response. The glutamatergic mechanism is thought to reduce the excessive neural excitation that underlies pathological worry. Several telehealth platforms accept GAD as a treatment indication.

Social Anxiety Disorder (SAD)

Social anxiety disorder has limited but growing evidence for ketamine response. The mechanism may involve reduced sensitivity to social threat cues and increased willingness to approach feared social situations. Integration work that involves behavioral practice in social situations (between sessions) may enhance the benefit.

Panic Disorder

Some patients with panic disorder, particularly with agoraphobia limiting their daily functioning, have responded to ketamine. The reduction in baseline anxiety and the neuroplastic window for building new, non-panic associations in previously avoided situations may be mechanisms.

Anxiety with Comorbid Depression

This is where ketamine is most solidly evidenced for anxiety. The majority of patients with treatment-resistant anxiety also have significant depression, and the clear antidepressant evidence likely encompasses significant anxiolytic benefit in these comorbid presentations.

Special Considerations for Anxiety Patients

Anticipatory Anxiety About the Session

Patients with anxiety disorders often experience significant anticipatory anxiety about the ketamine experience itself. The unknown quality of an altered state can activate anxiety rather than resolve it. Preparation is especially important:

• Talk with your provider about your specific fears
• Use the preparation period to practice relaxation and acceptance techniques
• Set the intention to approach the experience with curiosity rather than control
• Ensure your sitter is someone whose presence is calming (see our set and setting guide for preparation details)

The Risk of Paradoxical Anxiety During Sessions

Some patients with anxiety disorders experience initial heightening of anxiety as ketamine takes effect, before the dissociative state resolves it. Your provider should know your anxiety history so the dose can be titrated appropriately and so they can provide support if needed.

Having a clear protocol for what to do if you become acutely anxious during a session—speaking aloud to your sitter, using a grounding phrase—reduces the risk of a difficult experience.

Integration Focus for Anxiety

Integration after ketamine sessions for anxiety should specifically address:

• What patterns or beliefs underlie your anxiety
• What the session revealed about how you relate to fear or uncertainty
• Behavioral commitments—small steps toward avoided situations while the neuroplastic window is open
• Somatic practices to support nervous system regulation (breathwork, progressive muscle relaxation)

Anxiety and Benzodiazepine Use

Many patients with anxiety disorders are on benzodiazepines. This is an important interaction to discuss with your ketamine provider:

• Benzodiazepines can blunt the antidepressant and anxiolytic effects of ketamine
• The combination of benzodiazepines and ketamine at the time of a session may affect the quality of the experience
• Some providers recommend reducing benzodiazepine use before treatment courses

Do not stop or reduce benzodiazepines without your provider's guidance—abrupt cessation can cause withdrawal, including seizures in chronic heavy users. This requires medical supervision and planning.

Which Platforms Treat Anxiety?

All major telehealth ketamine platforms list anxiety as a treatment indication alongside depression. However, the treatment of anxiety—particularly complex, treatment-resistant anxiety—may benefit from platforms with stronger integration support:

• Therapist-integration platforms: Best for anxiety comorbid with significant trauma or for patients whose anxiety requires ongoing licensed therapist integration
• Comprehensive program platforms: Health coaching models can address anxiety patterns explicitly in integration sessions
• Subscription session platforms: Broad anxiety treatment experience; app-based tools may include anxiety-specific content

Monitoring Anxiety Outcomes

Your provider should track anxiety severity using validated measures—the GAD-7 (7-item generalized anxiety disorder scale) is standard. Ensure your provider administers this at baseline and at regular intervals so you have objective data on your response.

Subjective anxiety often fluctuates, and having validated scale scores helps distinguish real improvement from short-term relief, and helps identify when the treatment needs adjustment.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• NIMH: Depression — National Institute of Mental Health overview of depressive disorders, treatment-resistant forms, and emerging therapies
• WHO: Depression Fact Sheet — World Health Organization global data on depression prevalence, burden, and treatment approaches